May 16, 2014 I looked at it, and I've noticed lots of current ownership and recent buying in the last couple of quarters from big institutions like Fidelity, Vanguard, and Blackrock. And the founder of the company just took a new ~ 25% stake in the company in Q1. It may be worth a shot. What I usually do with these biotechs I come across that have something promising in trials or are going to the FDA for a decision is to buy both puts and calls on them that are a pretty good ways out as long as I can get them at a price I can live with. When it's a low priced stock like this one, I usually buy more calls than puts, since it's much closer to zero than it is to the $15 - $20 + price it will likely briefly swell up to IF it gets approval. Or if you feel better than average about the company itself, you can buy a small long stock position with a fairly long range put - if the approval goes through, the stock shoots up and you sell most or all of it ASAP after it's announced most likely outside of market hours, and you're only out the small premium you paid on the put that you won't exercise. If the approval is declined, you have downside protection with the put and either don't exercise your call or sell out of your small losing long position ASAP.